Friday, 16 October 2026European Markets

SALMONES CAMANCHAC And ACOMO Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - SALMONES CAMANCHAC (SACAM.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SALMONES CAMANCHAC (SACAM.OL) kr32.20 11.42% 3.92%
ACOMO (ACOMO.AS) €17.60 7.05% 11.27%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SALMONES CAMANCHAC (SACAM.OL)

11.42% Forward Dividend Yield and 3.92% Return On Equity

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. The company was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. is a subsidiary of Compañía Pesquera Camanchaca S.A.

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr1.2.

PE Ratio

SALMONES CAMANCHAC has a trailing twelve months price to earnings ratio of 26.83. Meaning, the purchaser of the share is investing kr26.83 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.92%.

Yearly Top and Bottom Value

SALMONES CAMANCHAC's stock is valued at kr32.20 at 06:30 EST, way below its 52-week high of kr49.00 and higher than its 52-week low of kr31.20.

Moving Average

SALMONES CAMANCHAC's value is under its 50-day moving average of kr35.69 and way below its 200-day moving average of kr40.58.

Volume

Today's last reported volume for SALMONES CAMANCHAC is 12 which is 98.19% below its average volume of 666.

More news about SALMONES CAMANCHAC.

2. ACOMO (ACOMO.AS)

7.05% Forward Dividend Yield and 11.27% Return On Equity

Acomo N.V., together with its subsidiaries, engages in sourcing, trading, processing, packaging, and distributing conventional and organic food ingredients and solutions for the food and beverage industry worldwide. It operates through five segments: Spices and Nuts, Edible Seeds, Organic Ingredients, Tea, and Food Solutions. The Spices and Nuts segment provides tropical products, including pepper, nutmeg, desiccated coconut, shelled and unshelled nuts, dried fruits, dehydrated vegetables, herbs, rice crackers, and snack products. Its Edible Seeds segment trades, processes, and distributes edible seeds, such as poppy, sesame, pumpkin, and flax, as well as sunflower seeds comprising in-kernel and shelled for the snack and retail industries; birdseeds for wildlife; and edible seeds to bakery, spice, and confectionery industries. The Organic Ingredients segment provides a range of organic food products and ingredients in various categories, including cocoa, coffee, fruit and vegetables, edible seeds, nuts and dried fruits, oils, and premium juice products. Its Tea segment trades, processes, and distributes through warehouses and blending facilities; and monitors and analyzes market development, and shares insight to customers to meet traditional consumer preferences, which include novel appetites for specialty tea. The Food Solutions segment produces and supplies culinary and functional ingredients, plant-based solutions, wet and dry blends, and spice mixes to food companies; and provides product development, manufacturing, packaging, distribution, and inventory management services. The company was formerly known as Amsterdam Commodities N.V. and changed its name to Acomo N.V. in June 2022. Acomo N.V. was founded in 1908 and is based in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, ACOMO has a trailing twelve months EPS of €1.55.

PE Ratio

ACOMO has a trailing twelve months price to earnings ratio of 11.35. Meaning, the purchaser of the share is investing €11.35 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.27%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.2%, now sitting on 1.38B for the twelve trailing months.

Volatility

ACOMO's last week, last month's, and last quarter's current intraday variation average was a negative 0.06%, a negative 0.47%, and a positive 0.90%.

ACOMO's highest amplitude of average volatility was 1.82% (last week), 1.19% (last month), and 0.90% (last quarter).

Yearly Top and Bottom Value

ACOMO's stock is valued at €17.60 at 06:30 EST, way under its 52-week high of €23.15 and higher than its 52-week low of €17.02.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ACOMO's stock is considered to be oversold (<=20).

More news about ACOMO.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com